Abbvie Inc (ABBV)

$229.83 +13.34 (6.16%)
Market Cap 382.49B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 21.71
Forward PE 15.14
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 5,533,035
Avg Vol 6,053,388
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 8%
Beta 0.32
Analysts Strong Sell
Price Target $251.55

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
pvll
pvll Jun. 22 at 6:55 PM
$ABBV good on ABBV for putting AI in their pills! Now turn your pill factories into data centers.
0 · Reply
breakoutstock
breakoutstock Jun. 22 at 6:47 PM
$NKTR pretty obvious they turned down an offer from $ABBV thid is a far superior drug. 🚀
0 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Jun. 22 at 6:18 PM
$ABBV just purchased $APGE for ELEVEN BILLION HOLY MOLY!! $VSEE has potential buyout or acquisition in place! EITHER WITH NASA OR ANOTHER US GOVERNMENT CONTRACT SOON HOLD EXTREMELY
0 · Reply
JFDI
JFDI Jun. 22 at 5:29 PM
$ABBV
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Jun. 22 at 5:28 PM
$SYRE 25% Trim Will ride to FDA approve Wutch $APGE $ABBV
0 · Reply
WallStWireAds
WallStWireAds Jun. 22 at 5:09 PM
$NVCT After Lilly and AbbVie, Haisco Picks Nuvectis Pharma for $1.46B Deal Spanning Two Late-Stage Assets with Best-in-Class Potential https://www.bioreview.com/after-lilly-and-abbvie-haisco-picks-nuvectis-pharma-for-1-46b-deal-spanning-two-late-stage-assets-with-best-in-class-potential/ $ABBV $LLY $NVS
0 · Reply
Gramma
Gramma Jun. 22 at 4:52 PM
$ABBV wow!!!
0 · Reply
usiv
usiv Jun. 22 at 4:44 PM
$ABBV it’s a weekly and daily breakout today.
0 · Reply
scalesojustice
scalesojustice Jun. 22 at 4:34 PM
$SLS $ABBV Buys APGE for 10.9 B and market cap rises 28 B. Money makes money....
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 22 at 4:15 PM
$SLS $ABBV $PFE $BMY 3 of the most powerful companies in oncology all have specific strategic reasons to own GPS after a positive REGAL readout. BMS needs to protect Onureg. AbbVie needs to protect Venetoclax. Merck needs to extend Keytruda past the patent cliff. And Ptizer just hired people who came from the exact companies that GPS is about to disrupt and know precisely what that disruption is worth. REGAL Phase 3 data after T1 halt= $120.00+ Longs are about to witness the most consequential and contested acquisition it has seen in a generation. Hold with conviction! ✌️🙏❤️‍🩹
0 · Reply
Latest News on ABBV
Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

Jun 22, 2026, 10:30 AM EDT - 4 hours ago

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

CRDO MU APGE

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 5 hours ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE

AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 6 hours ago

AbbVie Transcript: M&A announcement

AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 6 hours ago

AbbVie Slides: M&A announcement

AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 6 hours ago

AbbVie Press release: M&A announcement

5 Things to Know Before the Stock Market Opens

Jun 22, 2026, 8:56 AM EDT - 6 hours ago

5 Things to Know Before the Stock Market Opens

APGE CCL DRI FDX FDXF MKC MU

Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital

2026-06-22T12:24:03.000Z - 7 hours ago

Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital

APGE REGN

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 7 hours ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE

AbbVie to acquire Apogee Therapeutics for $10.9B in cash

2026-06-22T11:15:52.000Z - 8 hours ago

AbbVie to acquire Apogee Therapeutics for $10.9B in cash

APGE

AbbVie to acquire Apogee Therapeutics for $135.11 per share in cash, or $10.9B

2026-06-22T11:10:51.000Z - 8 hours ago

AbbVie to acquire Apogee Therapeutics for $135.11 per share in cash, or $10.9B

APGE

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

Jun 22, 2026, 7:06 AM EDT - 8 hours ago

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

APGE

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 8 hours ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

Jun 22, 2026, 7:00 AM EDT - 8 hours ago

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

APGE

Canaccord sees potential Apogee buyout as ‘huge win’ for sector

2026-06-22T10:48:07.000Z - 8 hours ago

Canaccord sees potential Apogee buyout as ‘huge win’ for sector

APGE CLDX CNTB EVMN KYMR NKTR

BTIG says others may be interested in Apogee Therapeutics

2026-06-22T10:40:59.000Z - 8 hours ago

BTIG says others may be interested in Apogee Therapeutics

APGE CBIO JBIO JNJ NVS ORKA PFE

AbbVie bid for Apogee Therapeutics makes sense, says Wells Fargo

2026-06-22T10:23:29.000Z - 9 hours ago

AbbVie bid for Apogee Therapeutics makes sense, says Wells Fargo

APGE REGN

AbbVie near deal to acquire Apogee Therapeutics, FT reports

2026-06-22T09:00:15.000Z - 10 hours ago

AbbVie near deal to acquire Apogee Therapeutics, FT reports

APGE

‘A Solid Fit’: JPMorgan Backs AbbVie’s Potential $11B Apogee Acquisition

2026-06-22T05:55:55.000Z - 13 hours ago

‘A Solid Fit’: JPMorgan Backs AbbVie’s Potential $11B Apogee Acquisition

APGE REGN SNY

AbbVie would gain an experimental eczema drug by buying biotech: report

Jun 20, 2026, 12:11 PM EDT - 2 days ago

AbbVie would gain an experimental eczema drug by buying biotech: report

APGE

M&A News: AbbVie Lining up an $11B Deal for Eczema Drug Maker Apogee Therapeutics

2026-06-19T17:25:03.000Z - 3 days ago

M&A News: AbbVie Lining up an $11B Deal for Eczema Drug Maker Apogee Therapeutics

APGE

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

Jun 19, 2026, 11:17 AM EDT - 3 days ago

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

APGE

AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 3 days ago

AbbVie Declares Quarterly Dividend

Allergan Aesthetics announces FDA approval of Skinvive by Juvederm

2026-06-16T12:07:55.000Z - 6 days ago

Allergan Aesthetics announces FDA approval of Skinvive by Juvederm

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

Jun 16, 2026, 8:00 AM EDT - 6 days ago

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

AbbVie presents new data on fixed-duration venetoclax-based combination at EHA

2026-06-12T09:21:51.000Z - 10 days ago

AbbVie presents new data on fixed-duration venetoclax-based combination at EHA

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Jun 12, 2026, 3:00 AM EDT - 10 days ago

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Jun 11, 2026, 7:14 AM EDT - 11 days ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ALKS AMGN GILD IBB IHE JNJ KYMR

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Jun 10, 2026, 11:47 AM EDT - 12 days ago

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:40 AM EDT - 13 days ago

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

Jun 8, 2026, 8:00 AM EDT - 14 days ago

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Jun 3, 2026, 7:04 PM EDT - 18 days ago

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

Jun 3, 2026, 3:30 AM EDT - 19 days ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

BIIB LLY ROP

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Jun 2, 2026, 8:00 AM EDT - 20 days ago

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

AbbVie announces EC authorizes expanded label for Venclyxto

2026-05-29T13:20:36.000Z - 24 days ago

AbbVie announces EC authorizes expanded label for Venclyxto

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

May 29, 2026, 8:00 AM EDT - 24 days ago

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

May 27, 2026, 6:18 PM EDT - 25 days ago

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

US FDA approves AbbVie's rare blood cancer drug

May 27, 2026, 3:33 PM EDT - 25 days ago

US FDA approves AbbVie's rare blood cancer drug

FDA approves AbbVie’s Decnupaz for blastic plasmacytoid dendritic cell neoplasm

2026-05-27T19:25:11.000Z - 25 days ago

FDA approves AbbVie’s Decnupaz for blastic plasmacytoid dendritic cell neoplasm

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

May 22, 2026, 8:00 AM EDT - 4 weeks ago

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

May 21, 2026, 6:46 PM EDT - 4 weeks ago

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

May 21, 2026, 4:10 PM EDT - 4 weeks ago

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 2:20 PM EDT - 5 weeks ago

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 6 weeks ago

AbbVie Transcript: AGM 2026

AbbVie to Present at the Bank of America Securities Healthcare Conference

May 6, 2026, 8:00 AM EDT - 6 weeks ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

May 5, 2026, 8:05 AM EDT - 6 weeks ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 3:05 PM EDT - 7 weeks ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

Big Pharma M&A set for mega year as patent expiries drive deal urgency

May 1, 2026, 10:03 AM EDT - 7 weeks ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Apr 30, 2026, 3:00 PM EDT - 7 weeks ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

Apr 30, 2026, 9:00 AM EDT - 7 weeks ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 7 weeks ago

AbbVie Earnings Call Transcript: Q1 2026

AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 7 weeks ago

AbbVie Earnings release: Q1 2026

AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 7 weeks ago

AbbVie Quarterly report: Q1 2026

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 7 weeks ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:50 AM EDT - 7 weeks ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

AbbVie Reports First-Quarter 2026 Financial Results

Apr 29, 2026, 7:47 AM EDT - 7 weeks ago

AbbVie Reports First-Quarter 2026 Financial Results

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Apr 28, 2026, 8:00 AM EDT - 7 weeks ago

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

Apr 28, 2026, 7:00 AM EDT - 7 weeks ago

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Apr 27, 2026, 8:05 AM EDT - 2 months ago

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:19 PM EDT - 2 months ago

US FDA declines to approve AbbVie's wrinkle treatment

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

Apr 23, 2026, 4:05 PM EDT - 2 months ago

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

AbbVie to build $1.4 billion manufacturing campus in North Carolina

Apr 22, 2026, 12:59 PM EDT - 2 months ago

AbbVie to build $1.4 billion manufacturing campus in North Carolina

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Apr 22, 2026, 12:02 PM EDT - 2 months ago

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Apr 20, 2026, 2:30 AM EDT - 2 months ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 14, 2026, 8:50 AM EDT - 2 months ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

Apr 13, 2026, 2:24 AM EDT - 2 months ago

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

Apr 12, 2026, 7:15 AM EDT - 2 months ago

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

Apr 8, 2026, 1:38 PM EDT - 2 months ago

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

Apr 8, 2026, 8:00 AM EDT - 2 months ago

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Apr 7, 2026, 9:53 AM EDT - 2 months ago

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Apr 7, 2026, 9:00 AM EDT - 2 months ago

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Swiss industry body says US tariffs on pharmaceuticals will harm patients

Apr 3, 2026, 11:08 AM EDT - 2 months ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

AMGN AZN BMY MRK NVO

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

Apr 2, 2026, 5:34 PM EDT - 2 months ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN NVO AMGN BMY MRK

pvll
pvll Jun. 22 at 6:55 PM
$ABBV good on ABBV for putting AI in their pills! Now turn your pill factories into data centers.
0 · Reply
breakoutstock
breakoutstock Jun. 22 at 6:47 PM
$NKTR pretty obvious they turned down an offer from $ABBV thid is a far superior drug. 🚀
0 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Jun. 22 at 6:18 PM
$ABBV just purchased $APGE for ELEVEN BILLION HOLY MOLY!! $VSEE has potential buyout or acquisition in place! EITHER WITH NASA OR ANOTHER US GOVERNMENT CONTRACT SOON HOLD EXTREMELY
0 · Reply
JFDI
JFDI Jun. 22 at 5:29 PM
$ABBV
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Jun. 22 at 5:28 PM
$SYRE 25% Trim Will ride to FDA approve Wutch $APGE $ABBV
0 · Reply
WallStWireAds
WallStWireAds Jun. 22 at 5:09 PM
$NVCT After Lilly and AbbVie, Haisco Picks Nuvectis Pharma for $1.46B Deal Spanning Two Late-Stage Assets with Best-in-Class Potential https://www.bioreview.com/after-lilly-and-abbvie-haisco-picks-nuvectis-pharma-for-1-46b-deal-spanning-two-late-stage-assets-with-best-in-class-potential/ $ABBV $LLY $NVS
0 · Reply
Gramma
Gramma Jun. 22 at 4:52 PM
$ABBV wow!!!
0 · Reply
usiv
usiv Jun. 22 at 4:44 PM
$ABBV it’s a weekly and daily breakout today.
0 · Reply
scalesojustice
scalesojustice Jun. 22 at 4:34 PM
$SLS $ABBV Buys APGE for 10.9 B and market cap rises 28 B. Money makes money....
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 22 at 4:15 PM
$SLS $ABBV $PFE $BMY 3 of the most powerful companies in oncology all have specific strategic reasons to own GPS after a positive REGAL readout. BMS needs to protect Onureg. AbbVie needs to protect Venetoclax. Merck needs to extend Keytruda past the patent cliff. And Ptizer just hired people who came from the exact companies that GPS is about to disrupt and know precisely what that disruption is worth. REGAL Phase 3 data after T1 halt= $120.00+ Longs are about to witness the most consequential and contested acquisition it has seen in a generation. Hold with conviction! ✌️🙏❤️‍🩹
0 · Reply
Olivia_Strickland
Olivia_Strickland Jun. 22 at 3:59 PM
$ABBV breakout, up 7.0% on 3,506,920 volume. this is what my scanner flagged: https://tapeboard.com/scanner?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=abbv-bk-up-scanner&utm_term=scanner&s=ABBV
0 · Reply
briefingcom
briefingcom Jun. 22 at 3:21 PM
$ABBV: AbbVie is trading higher after agreeing to buy Apogee Therapeutics for $135.11/share in cash, valuing $APGE at about $10.9 bln. The deal deepens ABBV’s immunology pipeline, but investors will be watching the price tag, clinical risk, and long path to EPS accretion. See the full analysis: https://www.briefing.com/story-stocks/archive/2026/6/22/abbvie-catches-apogee-fever-109b-deal-expands-immunology-and-asthma-pipeline?utm_campaign=storystocks&utm_medium=social&utm_source=st&utm_content=link $APOG #Abbvie $LLY $JNJ #Apogee #biotech #pharma #Immunology #asthma #healthcare #health
0 · Reply
ians
ians Jun. 22 at 3:02 PM
$VKTX Congrats to $APGE shareholders!👏 Zumilokibart def. Works for AD but I believe $ABBV is just starting with appetizers. Why? Cuz Zumi is at least 2-3yrs away from hittin FDA approval. By then, VK2735 will be FDA approved & will be bringing in $$$$. ABBV is still on top of my list of US BPs interested in building out its cardio-metabolic franchise. So, a bid from it is not out of the ?. And if APGE can command $11B, VK2735 SC + PO is worth at least $15-18B rn IMHO 👍☘️💎 https://finance.yahoo.com/healthcare/articles/abbvie-strikes-10-9-billion-125837267.html
0 · Reply
TeenageMutantNinjaTrader
TeenageMutantNinjaTrader Jun. 22 at 3:00 PM
$ABBV up on an acquisition? What am i missing
0 · Reply
TheLec
TheLec Jun. 22 at 2:54 PM
$ABBV booom
0 · Reply
prismmarketview
prismmarketview Jun. 22 at 2:30 PM
AbbVie just paid $10.9B for Apogee — and won't see it boost earnings until 2032. So why the premium? One word: pipeline. The crown jewel is zumilokibart, a phase 2 atopic dermatitis candidate, plus an asthma combo therapy. $ABBV $APGE https://prismmarketview.com/abbvie-bets-big-on-immunology-with-10-9-billion-apogee-acquisition/
0 · Reply
Options_Destroyer
Options_Destroyer Jun. 22 at 2:06 PM
$ABBV keeper
0 · Reply
Project_Profit
Project_Profit Jun. 22 at 1:57 PM
$BCRX M&A juicing Bios today. Thank you $ABBV
1 · Reply
OpenOutcrier
OpenOutcrier Jun. 22 at 12:50 PM
$APGE (+46.9% pre) $ABBV AbbVie bets $10.9 billion on Apogee in next-generation immunology growth push - CNBC https://ooc.bz/l/105699
0 · Reply
briefingcom
briefingcom Jun. 22 at 12:24 PM
$ABBV: AbbVie (+2%) and Apogee Therapeutics $APGE (+46.8%) enter into a definitive agreement under which AbbVie will acquire Apogee for $135.11 per share in cash.
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Jun. 22 at 12:06 PM
$APGE $ABBV rumored to buy Was just about to post here today Fits my bio space, DERM, Respiratory, And now Gastro. 😭 $SYRE $ORKA
0 · Reply
notreload_ai
notreload_ai Jun. 22 at 11:36 AM
$ABBV has agreed to buy $APGE for $10.9B in cash ($135.11 per share). The deal adds zumilokibart, a long-acting immunology drug for atopic dermatitis and asthma, to AbbVie’s pipeline.
0 · Reply